Exhibit 99.1
 | |||||
AMNEAL REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS
‒ Q1 2023 Net Revenue of $558 million; GAAP Net Loss of $7 million; Diluted Loss per Share of $0.05 ‒
‒ Adjusted EBITDA (1) of $116 million; Adjusted Diluted EPS (1) of $0.12 ‒
‒ Affirming 2023 Full Year Guidance ‒
BRIDGEWATER, NJ, May 5, 2023 - Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced its actual results today for the first quarter ended March 31, 2023.
“We are very pleased with our strong first quarter results and start to 2023. We are confident in our continued momentum driven by the broad-based strength of our diverse and increasingly complex generics portfolio, uptake of our new biosimilars, expansion of our AvKARE business, and the continued growth and potential of our specialty portfolio. Today we are also happy to announce the successful inspection of our fourth and largest injectables facility, and we are working closely with the U.S. FDA ahead of our June 30th PDUFA date for IPX203 in Parkinson’s. These are key building blocks and good indicators of our continued success as we execute our strategy, drive sustainable long-term growth, reduce debt, and create value for all of our stakeholders,” said Chirag and Chintu Patel, Co-Chief Executive Officers.
Net revenue in the first quarter of 2023 was $558 million, an increase of 12% compared to $498 million in the first quarter of 2022. The increase was driven by growth across all three business segments with strong performance across our complex Generics portfolio, growth of Rytary® and Unithroid® in Specialty, and continued expansion of AvKARE’s distribution channel.
Net loss attributable to Amneal Pharmaceuticals, Inc. was $7 million in the first quarter of 2023 compared to a net loss of $2 million in the first quarter of 2022. Adjusted EBITDA(1) in the first quarter of 2023 was $116 million, an increase of 16% compared to the first quarter of 2022, reflective of robust revenue performance and favorable operating expenses. Diluted loss per share in the first quarter of 2023 was $0.05 compared to a loss of $0.01 for the first quarter of 2022. Adjusted diluted EPS(1) in both the first quarter of 2023 and 2022 was $0.12.
(1) See “Non-GAAP Financial Measures” below.
Affirming Full Year 2023 Guidance
The Company is affirming its previously provided full year 2023 guidance.
Full Year 2023 Guidance | |||||
| Net revenue | $2.25 billion - $2.35 billion | ||||
Adjusted EBITDA (1) | $500 million - $530 million | ||||
Adjusted diluted EPS (2) | $0.40 - $0.50 | ||||
Operating cash flow (3) | $200 million - $230 million | ||||
| Capital expenditures | $50 million - $60 million | ||||
Weighted average diluted shares outstanding (4) | Approximately 307 million | ||||
(1) Includes 100% of EBITDA from the AvKARE acquisition. See also “Non-GAAP Financial Measures” below.
(2) Accounts for 35% non-controlling interest in AvKARE. See also “Non-GAAP Financial Measures” below.
(3) Represents cash provided by operating activities. Guidance does not contemplate one time and non-recurring items such as legal settlements and other discrete items.
(4) Assumes the weighted average diluted shares outstanding of class A and class B common stock under the if-converted method.
1
Amneal’s 2023 estimates are based on management’s current expectations, including with respect to prescription trends, pricing levels, the timing of future product launches, the costs incurred and benefits realized of restructuring activities, and our long-term strategy. The Company’s financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The Company cannot provide a reconciliation between non-GAAP projections and the most directly comparable measures in accordance with GAAP without unreasonable efforts because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items required for the reconciliation. The items include, but are not limited to, acquisition-related expenses, restructuring expenses and benefits, asset impairments, legal settlements, and other gains and losses. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results.
Conference Call Information
Amneal will host a conference call and live webcast at 8:30 am Eastern Time on May 5, 2023 to discuss its results. The live webcast and presentation will be accessible through the Investor Relations section of the Company’s website at https://investors.amneal.com. To access the call through a conference line, dial 1 (833) 470-1428 (in the U.S.) or for a list of toll-free international numbers, visit this website: https://www.netroadshow.com/events/global-numbers?confId=49327. The access code for the call is 957420. A replay of the conference call will be posted shortly after the call and will be available for seven days. To access the replay, dial 1 (866) 813-9403 (in the U.S.) or for a list of toll-free international numbers, visit this website: https://www.netroadshow.com/events/global-numbers?confId=49327. The access code for the replay is 704782.
About Amneal
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully integrated global essential medicines company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of approximately 270 generic and specialty pharmaceuticals, primarily within the United States. In its Generics segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com.
Cautionary Statement on Forward-Looking Statements
Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations, including international expansion; expected or estimated operating results and financial performance; the Company’s growth prospects and opportunities as well as its strategy for growth; product development and launches; the successful commercialization and market acceptance of new products, and other non-historical statements. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements.
The reader is cautioned not to rely on these forward-looking statements. These forward-looking statements are based on current expectations of future events, including with respect to future market conditions, company performance and financial results, operational investments, business prospects, new strategies and growth initiatives, the competitive environment, and other events. If the underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company.
Such risks and uncertainties include, but are not limited to: our ability to successfully develop, license, acquire and commercialize new products on a timely basis; the competition we face in the pharmaceutical industry from brand and generic drug product companies, and the impact of that competition on our ability to set prices; our ability to obtain exclusive marketing rights for our products; our ability to manage our growth through acquisitions and otherwise; our revenues are derived from the sales of a limited number of products, a substantial portion of which are through a limited number of customers; the continuing trend of consolidation of certain customer groups; our dependence on third-party suppliers and distributors for raw materials for our products and certain finished goods; our substantial amount of indebtedness and our ability to generate sufficient cash to service our indebtedness in the future, and the impact of interest rate fluctuations on such indebtedness; our ability to secure satisfactory terms when negotiating a refinancing or other new indebtedness; our dependence on third-party agreements for a portion of our product offerings; legal, regulatory and legislative efforts by our brand competitors to deter competition from our generic alternatives; risks related to federal regulation of arrangements between manufacturers of branded and generic products; our reliance on certain licenses to proprietary technologies from time to time; the significant amount of resources we expend on research and development; the risk of product liability and other claims against us by consumers and other third parties; risks related to changes in the regulatory environment, including U.S. federal
2
and state laws related to healthcare fraud abuse and health information privacy and security and changes in such laws; changes to Food and Drug Administration product approval requirements; the impact of healthcare reform and changes in coverage and reimbursement levels by governmental authorities and other third-party payers; our potential expansion into additional international markets subjecting us to increased regulatory, economic, social and political uncertainties, including bank failures; our ability to identify, make and integrate acquisitions or investments in complementary businesses and products on advantageous terms; the impact of global economic, political or other catastrophic events; our ability to attract, hire and retain highly skilled personnel; our obligations under a tax receivable agreement may be significant; and the high concentration of ownership of our Class A Common Stock and the fact that we are controlled by the Amneal Group. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof.
Non-GAAP Financial Measures
This release includes certain non-GAAP financial measures, including EBITDA, adjusted EBITDA, and adjusted diluted EPS, which are intended as supplemental measures of the Company’s performance that are not required by or presented in accordance with GAAP. Adjusted diluted EPS reflects diluted earnings per share based on adjusted net income, which is net loss adjusted to (A) exclude (i) non-cash interest, (ii) GAAP provision for (benefit from) income taxes, (iii) amortization, (iv) stock-based compensation, (v) acquisition, site closure expenses, and idle facility expenses, (vi) restructuring and other charges, (vii) charges (credits) related to legal matters, including interest, net, (viii) asset impairment charges, (ix) regulatory approval milestone, (x) change in fair value of contingent consideration, (xi) other, (xii) net income attributable to non-controlling interests not associated with class B common stock, and (B) include non-GAAP provision for income taxes. Non-GAAP adjusted EPS is calculated assuming the weighted average diluted shares outstanding of class A and class B common stock under the if-converted method.
Management uses these non-GAAP measures internally to evaluate and manage the Company’s operations and to better understand its business because they facilitate a comparative assessment of the Company’s operating performance relative to its performance based on results calculated under GAAP. These non-GAAP measures also isolate the effects of some items that vary from period to period without any correlation to core operating performance and eliminate certain charges that management believes do not reflect the Company’s operations and underlying operational performance. The compensation committee of the Company’s board of directors also uses certain of these measures to evaluate management’s performance and set its compensation. The Company believes that these non-GAAP measures also provide useful information to investors regarding certain financial and business trends relating to the Company’s financial condition and operating results facilitates an evaluation of the financial performance of the Company and its operations on a consistent basis. Providing this information therefore allows investors to make independent assessments of the Company’s financial performance, results of operations and trends while viewing the information through the eyes of management.
These non-GAAP measures are subject to limitations. The non-GAAP measures presented in this release may not be comparable to similarly titled measures used by other companies because other companies may not calculate one or more in the same manner. Additionally, the non-GAAP performance measures exclude significant expenses and income that are required by GAAP to be recorded in the Company’s financial statements; do not reflect changes in, or cash requirements for, working capital needs; and do not reflect interest expense, or the requirements necessary to service interest or principal payments on debt. Further, our historical adjusted results are not intended to project our adjusted results of operations or financial position for any future period. To compensate for these limitations, management presents and considers these non-GAAP measures in conjunction with the Company’s GAAP results; no non-GAAP measure should be considered in isolation from or as alternatives to any measure determined in accordance with GAAP. Readers should review the reconciliations included below, and should not rely on any single financial measure to evaluate the Company’s business.
A reconciliation of each historical non-GAAP measure to the most directly comparable GAAP measure is set forth below.
Contact
Anthony DiMeo
Head of Investor Relations
anthony.dimeo@amneal.com
3
Amneal Pharmaceuticals, Inc.
Consolidated Statements of Operations
(Unaudited; In thousands, except per share amounts)
| Three Months Ended March 31, | |||||||||||
| 2023 | 2022 | ||||||||||
| Net revenue | $ | 557,540 | $ | 497,633 | |||||||
| Cost of goods sold | 379,354 | 323,062 | |||||||||
| Gross profit | 178,186 | 174,571 | |||||||||
| Selling, general and administrative | 102,096 | 98,665 | |||||||||
| Research and development | 38,690 | 52,798 | |||||||||
| Intellectual property legal development expenses | 1,644 | 764 | |||||||||
| Acquisition, transaction-related and integration expenses | — | 434 | |||||||||
| Restructuring and other charges | 510 | 731 | |||||||||
| Change in fair value of contingent consideration | 2,457 | 200 | |||||||||
| Credit related to legal matters, net | (436) | (2,326) | |||||||||
| Other operating income | (1,224) | — | |||||||||
| Operating income | 34,449 | 23,305 | |||||||||
| Other (expense) income: | |||||||||||
| Interest expense, net | (49,315) | (33,335) | |||||||||
| Foreign exchange gain (loss), net | 1,901 | (2,013) | |||||||||
| Other income, net | 3,539 | 2,122 | |||||||||
| Total other expense, net | (43,875) | (33,226) | |||||||||
| Loss before income taxes | (9,426) | (9,921) | |||||||||
| Provision for (benefit from) income taxes | 668 | (3,461) | |||||||||
| Net loss | (10,094) | (6,460) | |||||||||
| Less: Net loss attributable to non-controlling interests | 3,151 | 4,742 | |||||||||
| Net loss attributable to Amneal Pharmaceuticals, Inc. before accretion of redeemable non-controlling interest | (6,943) | (1,718) | |||||||||
| Accretion of redeemable non-controlling interest | — | (438) | |||||||||
| Net loss attributable to Amneal Pharmaceuticals, Inc. | $ | (6,943) | $ | (2,156) | |||||||
| Net loss per share attributable to Amneal Pharmaceuticals, Inc.'s class A common stockholders: | |||||||||||
| Basic and diluted | $ | (0.05) | $ | (0.01) | |||||||
| Weighted-average common shares outstanding: | |||||||||||
| Basic and diluted | 152,109 | 149,892 | |||||||||
4
Amneal Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheets
(Unaudited; In thousands)
| March 31, 2023 | December 31, 2022 | ||||||||||
| Assets | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 144,674 | $ | 25,976 | |||||||
| Restricted cash | 6,395 | 9,251 | |||||||||
| Trade accounts receivable, net | 545,760 | 741,791 | |||||||||
| Inventories | 529,042 | 530,735 | |||||||||
| Prepaid expenses and other current assets | 81,424 | 103,565 | |||||||||
| Related party receivables | 30 | 500 | |||||||||
| Total current assets | 1,307,325 | 1,411,818 | |||||||||
| Property, plant and equipment, net | 462,606 | 469,815 | |||||||||
| Goodwill | 599,156 | 598,853 | |||||||||
| Intangible assets, net | 1,055,319 | 1,096,093 | |||||||||
| Operating lease right-of-use assets | 36,127 | 38,211 | |||||||||
| Operating lease right-of-use assets - related party | 17,244 | 17,910 | |||||||||
| Financing lease right-of-use assets | 62,400 | 63,424 | |||||||||
| Other assets | 86,428 | 103,217 | |||||||||
| Total assets | $ | 3,626,605 | $ | 3,799,341 | |||||||
| Liabilities and Stockholders' Equity | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable and accrued expenses | $ | 467,421 | $ | 538,199 | |||||||
| Current portion of liabilities for legal matters | 76,317 | 107,483 | |||||||||
| Revolving credit facility | 100,000 | 60,000 | |||||||||
| Current portion of long-term debt, net | 29,965 | 29,961 | |||||||||
| Current portion of operating lease liabilities | 9,017 | 8,321 | |||||||||
| Current portion of operating lease liabilities - related party | 2,930 | 2,869 | |||||||||
| Current portion of financing lease liabilities | 3,309 | 3,488 | |||||||||
| Related party payables - short term | 14,750 | 2,479 | |||||||||
| Total current liabilities | 703,709 | 752,800 | |||||||||
| Long-term debt, net | 2,561,724 | 2,591,981 | |||||||||
| Note payable - related party | 40,128 | 39,706 | |||||||||
| Operating lease liabilities | 30,782 | 32,126 | |||||||||
| Operating lease liabilities - related party | 15,163 | 15,914 | |||||||||
| Financing lease liabilities | 60,241 | 60,769 | |||||||||
| Related party payables - long term | 11,207 | 9,649 | |||||||||
| Other long-term liabilities | 41,456 | 87,468 | |||||||||
| Total long-term liabilities | 2,760,701 | 2,837,613 | |||||||||
| Redeemable non-controlling interests | 27,527 | 24,949 | |||||||||
| Total stockholders' equity | 134,668 | 183,979 | |||||||||
| Total liabilities and stockholders' equity | $ | 3,626,605 | $ | 3,799,341 | |||||||
5
Amneal Pharmaceuticals, Inc.
Consolidated Statements of Cash Flows
(Unaudited; In thousands)
| Three Months Ended March 31, | |||||||||||
| 2023 | 2022 | ||||||||||
| Cash flows from operating activities: | |||||||||||
| Net loss | $ | (10,094) | $ | (6,460) | |||||||
| Adjustments to reconcile net loss to net cash provided by operating activities: | |||||||||||
| Depreciation and amortization | 58,150 | 57,815 | |||||||||
| Unrealized foreign currency (gain) loss | (1,987) | 3,140 | |||||||||
| Amortization of debt issuance costs and discount | 2,058 | 2,195 | |||||||||
| Change in fair value of contingent consideration | 2,457 | 200 | |||||||||
| Stock-based compensation | 7,596 | 8,065 | |||||||||
| Inventory provision | 25,204 | 3,578 | |||||||||
| Other operating charges and credits, net | 2,047 | 1,155 | |||||||||
| Changes in assets and liabilities: | |||||||||||
| Trade accounts receivable, net | 195,970 | 124,268 | |||||||||
| Inventories | (22,508) | (25,549) | |||||||||
| Prepaid expenses, other current assets and other assets | 29,160 | (4,423) | |||||||||
| Related party receivables | 470 | 4 | |||||||||
| Accounts payable, accrued expenses and other liabilities | (150,483) | (48,777) | |||||||||
| Related party payables | 1,672 | 5,132 | |||||||||
| Net cash provided by operating activities | 139,712 | 120,343 | |||||||||
| Cash flows from investing activities: | |||||||||||
| Purchases of property, plant and equipment | (9,688) | (10,793) | |||||||||
| Acquisition of business | — | (84,714) | |||||||||
| Acquisition of intangible assets | (338) | — | |||||||||
| Deposits for future acquisition of property, plant, and equipment | (1,711) | (1,888) | |||||||||
| Net cash used in investing activities | (11,737) | (97,395) | |||||||||
| Cash flows from financing activities: | |||||||||||
| Payments of principal on debt, revolving credit facility, financing leases and other | (72,659) | (9,796) | |||||||||
| Borrowings on revolving credit facility | 80,000 | — | |||||||||
| Proceeds from exercise of stock options | — | 111 | |||||||||
| Employee payroll tax withholding on restricted stock unit vesting | (2,022) | (3,001) | |||||||||
| Payments of deferred consideration for acquisitions - related party | — | (43,998) | |||||||||
| Acquisition of redeemable non-controlling interest | — | (1,722) | |||||||||
| Tax distributions to non-controlling interests | (18,219) | (3,164) | |||||||||
| Net cash used in financing activities | (12,900) | (61,570) | |||||||||
| Effect of foreign exchange rate on cash | 767 | (1,572) | |||||||||
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 115,842 | (40,194) | |||||||||
| Cash, cash equivalents, and restricted cash - beginning of period | 35,227 | 256,739 | |||||||||
| Cash, cash equivalents, and restricted cash - end of period | $ | 151,069 | $ | 216,545 | |||||||
| Cash and cash equivalents - end of period | $ | 144,674 | $ | 210,477 | |||||||
| Restricted cash - end of period | 6,395 | 6,068 | |||||||||
| Cash, cash equivalents, and restricted cash - end of period | $ | 151,069 | $ | 216,545 | |||||||
6
Amneal Pharmaceuticals, Inc.
Non-GAAP Reconciliations
(Unaudited, In thousands)
Reconciliation of Net Loss to EBITDA and Adjusted EBITDA
| Three Months Ended March 31, | |||||||||||
| 2023 | 2022 | ||||||||||
| Net loss | $ | (10,094) | $ | (6,460) | |||||||
| Adjusted to add: | |||||||||||
| Interest expense, net | 49,315 | 33,335 | |||||||||
| Provision for (benefit from) income taxes | 668 | (3,461) | |||||||||
| Depreciation and amortization | 58,150 | 57,815 | |||||||||
| EBITDA (Non-GAAP) | $ | 98,039 | $ | 81,229 | |||||||
| Adjusted to add (deduct): | |||||||||||
| Stock-based compensation expense | 7,596 | 8,065 | |||||||||
Acquisition, site closure, and idle facility expenses (1) | 2,701 | 5,589 | |||||||||
| Restructuring and other charges | 411 | 731 | |||||||||
Charges (credits) related to legal matters, net (2) | 4,064 | (2,326) | |||||||||
| Asset impairment charges | 733 | — | |||||||||
| Foreign exchange (gain) loss | (1,901) | 2,013 | |||||||||
| Change in fair value of contingent consideration | 2,457 | 200 | |||||||||
| Regulatory approval milestone | — | 5,000 | |||||||||
| Other | 2,080 | (641) | |||||||||
| Adjusted EBITDA (Non-GAAP) | $ | 116,180 | $ | 99,860 | |||||||
7
Amneal Pharmaceuticals, Inc.
Non-GAAP Reconciliations
(Unaudited; In thousands, except per share amounts)
Reconciliation of Net Loss to Adjusted Net Income and Calculation of Adjusted Diluted Earnings Per Share
| Three Months Ended March 31, | |||||||||||
| 2023 | 2022 | ||||||||||
Net loss | $ | (10,094) | $ | (6,460) | |||||||
| Adjusted to add (deduct): | |||||||||||
Non-cash interest | 1,841 | 1,982 | |||||||||
GAAP provision for (benefit from) income taxes | 668 | (3,461) | |||||||||
Amortization | 39,611 | 39,152 | |||||||||
Stock-based compensation expense | 7,596 | 8,065 | |||||||||
Acquisition, site closure expenses, and idle facility expenses (1) | 2,701 | 5,589 | |||||||||
Restructuring and other charges | 411 | 731 | |||||||||
Charges (credits) related to legal matters, including interest, net (2) | 4,882 | (2,326) | |||||||||
Asset impairment charges | 733 | — | |||||||||
Regulatory approval milestone | — | 5,000 | |||||||||
| Change in fair value of contingent consideration | 2,457 | 200 | |||||||||
Other | 2,229 | (500) | |||||||||
Provision for income taxes (3) | (10,829) | (10,185) | |||||||||
Net income attributable to non-controlling interests not associated with our class B common stock | (5,395) | (2,199) | |||||||||
| Adjusted net income (Non-GAAP) | $ | 36,811 | $ | 35,588 | |||||||
Weighted average diluted shares outstanding (Non-GAAP) (4) | 306,370 | 304,630 | |||||||||
Adjusted diluted earnings per share (Non-GAAP) | $ | 0.12 | $ | 0.12 | |||||||
8
Amneal Pharmaceuticals, Inc.
Non-GAAP Reconciliations
(Unaudited; In thousands)
Explanations for Reconciliations of Net Loss to EBITDA and Adjusted EBITDA and
Net Loss to Adjusted Net Income and Calculation of Adjusted Diluted Earnings per Share
(1) | Acquisition, site closure, and idle facility expenses for the three months ended March 31, 2023 primarily included site closure costs associated with the planned cessation of manufacturing at our Hauppauge, NY facility. Acquisition, site closure, and idle facility expenses for the three months ended March 31, 2022 primarily included (i) transaction and integration costs associated with the acquisition of the baclofen franchise from certain entities affiliated with Saol International Limited; (ii) integration costs associated with the acquisition of Puniska Healthcare Pvt. Ltd.; and (iii) site closure costs associated with the planned cessation of manufacturing at our Hauppauge, NY facility. | |||||||||||||
| (2) | For the three months ended March 31, 2023 charges (credits) related to legal matters, net included charges of $4.9 million for legal proceedings. For the three months ended March 31, 2022, we recorded a net credit of $2.3 million for an insurance recovery of $4.0 million, partially offset by charges for legal proceedings. | |||||||||||||
| (3) | The non-GAAP effective tax rates for the three months ended March 31, 2023 and 2022 were 22.7% and 22.3%, respectively. | |||||||||||||
| (4) | Weighted average diluted shares outstanding consisted of class A common stock and class B common stock under the if-converted method. | |||||||||||||
9
Amneal Pharmaceuticals, Inc.
Generics Segment
Reconciliation of GAAP to Non-GAAP Operating Results (1)
(Unaudited; In thousands)
| Three Months Ended March 31, 2023 | Three Months Ended March 31, 2022 | ||||||||||||||||||||||||||||||||||
| As Reported | Adjustments | Non-GAAP | As Reported | Adjustments | Non-GAAP | ||||||||||||||||||||||||||||||
| Net revenue | $ | 343,806 | $ | — | $ | 343,806 | $ | 317,747 | $ | — | $ | 317,747 | |||||||||||||||||||||||
Cost of goods sold (2) | 230,551 | (15,442) | 215,109 | 199,030 | (15,091) | 183,939 | |||||||||||||||||||||||||||||
| Gross profit | 113,255 | 15,442 | 128,697 | 118,717 | 15,091 | 133,808 | |||||||||||||||||||||||||||||
| Gross margin % | 32.9 | % | 37.4 | % | 37.4 | % | 42.1 | % | |||||||||||||||||||||||||||
Selling, general and administrative (3) | 27,600 | (1,279) | 26,321 | 27,593 | (6,250) | 21,343 | |||||||||||||||||||||||||||||
Research and development (4) | 32,359 | (943) | 31,416 | 43,221 | (1,159) | 42,062 | |||||||||||||||||||||||||||||
| Intellectual property legal development expenses | 1,624 | — | 1,624 | 772 | — | 772 | |||||||||||||||||||||||||||||
| Restructuring and other charges | 99 | — | 99 | 206 | (206) | — | |||||||||||||||||||||||||||||
(Credits) charges related to legal matters, net (5) | (2,444) | (2,056) | (4,500) | 1,674 | (1,674) | — | |||||||||||||||||||||||||||||
| Other operating income | (1,224) | — | (1,224) | — | — | — | |||||||||||||||||||||||||||||
| Operating income | $ | 55,241 | $ | 19,720 | $ | 74,961 | $ | 45,251 | $ | 24,380 | $ | 69,631 | |||||||||||||||||||||||
(1) | Operating results for the sale of Amneal products by AvKARE were included in our Generics segment. | |||||||||||||
(2) | Adjustments for the three months ended March 31, 2023 and 2022, respectively, were comprised of stock-based compensation expense ($1.7 million and $1.5 million), amortization expense ($10.8 million and $9.3 million), site closure and idle facility expenses ($2.1 million and $4.6 million), asset impairment charges ($0.7 million and none), and other ($0.1 million and $(0.3) million). | |||||||||||||
(3) | Adjustments for the three months ended March 31, 2023 and 2022, respectively, were comprised of stock-based compensation expense ($0.7 million and $0.7 million), a regulatory approval milestone (none and $5.0 million), and site closure costs ($0.6 million and $0.6 million). | |||||||||||||
(4) | Adjustments for the three months ended March 31, 2023 and 2022 were comprised of stock-based compensation expense. | |||||||||||||
(5) | Adjustments for the three months ended March 31, 2023 and 2022 were comprised of charges for legal proceedings. | |||||||||||||
10
Amneal Pharmaceuticals, Inc.
Specialty Segment
Reconciliation of GAAP to Non-GAAP Operating Results
(Unaudited; In thousands)
| Three Months Ended March 31, 2023 | Three Months Ended March 31, 2022 | ||||||||||||||||||||||||||||||||||
| As Reported | Adjustments | Non-GAAP | As Reported | Adjustments | Non-GAAP | ||||||||||||||||||||||||||||||
| Net revenue | $ | 91,678 | $ | — | $ | 91,678 | $ | 85,086 | $ | — | $ | 85,086 | |||||||||||||||||||||||
Cost of goods sold (1) | 43,191 | (26,183) | 17,008 | 43,853 | (26,653) | 17,200 | |||||||||||||||||||||||||||||
| Gross profit | 48,487 | 26,183 | 74,670 | 41,233 | 26,653 | 67,886 | |||||||||||||||||||||||||||||
| Gross margin % | 52.9 | % | 81.4 | % | 48.5 | % | 79.8 | % | |||||||||||||||||||||||||||
Selling, general and administrative (2) | 22,379 | (186) | 22,193 | 24,400 | (613) | 23,787 | |||||||||||||||||||||||||||||
Research and development (2) | 6,331 | (389) | 5,942 | 9,577 | (326) | 9,251 | |||||||||||||||||||||||||||||
| Intellectual property legal development expenses (credit) | 20 | — | 20 | (8) | — | (8) | |||||||||||||||||||||||||||||
Change in fair value of contingent consideration (3) | 2,457 | (2,457) | — | 200 | (200) | — | |||||||||||||||||||||||||||||
| Operating income | $ | 17,300 | $ | 29,215 | $ | 46,515 | $ | 7,064 | $ | 27,792 | $ | 34,856 | |||||||||||||||||||||||
(1) | Adjustments for the three months ended March 31, 2023 and 2022 were comprised of amortization expense. | |||||||||||||
(2) | Adjustments for the three months ended March 31, 2023 and 2022 were comprised of stock-based compensation expense. | |||||||||||||
(3) | Contingent consideration was recorded in connection with the acquisition of the baclofen franchise from certain entities affiliated with Saol International Limited and the acquisition of Kashiv Specialty Pharmaceuticals, LLC. | |||||||||||||
11
Amneal Pharmaceuticals, Inc.
AvKARE Segment
Reconciliation of GAAP to Non-GAAP Operating Results (1)
(Unaudited; In thousands)
| Three Months Ended March 31, 2023 | Three Months Ended March 31, 2022 | ||||||||||||||||||||||||||||||||||
| As Reported | Adjustments | Non-GAAP | As Reported | Adjustments | Non-GAAP | ||||||||||||||||||||||||||||||
| Net revenue | $ | 122,056 | $ | — | $ | 122,056 | $ | 94,800 | $ | — | $ | 94,800 | |||||||||||||||||||||||
| Cost of goods sold | 105,612 | — | 105,612 | 80,179 | — | 80,179 | |||||||||||||||||||||||||||||
| Gross profit | 16,444 | — | 16,444 | 14,621 | — | 14,621 | |||||||||||||||||||||||||||||
| Gross margin % | 13.5 | % | 13.5 | % | 15.4 | % | 15.4 | % | |||||||||||||||||||||||||||
Selling, general and administrative (2) | 12,940 | (3,764) | 9,176 | 13,410 | (4,526) | 8,884 | |||||||||||||||||||||||||||||
| Operating income | $ | 3,504 | $ | 3,764 | $ | 7,268 | $ | 1,211 | $ | 4,526 | $ | 5,737 | |||||||||||||||||||||||
(1) | Operating results for the sale of Amneal products by AvKARE were included in our Generics segment. | |||||||||||||
(2) | Adjustments for the three months ended March 31, 2023 and 2022, respectively, were comprised of amortization expense ($4.2 million and $4.9 million), and other (($0.4) million in each period). | |||||||||||||
12